期刊
ONCOLOGIST
卷 28, 期 7, 页码 628-632出版社
OXFORD UNIV PRESS
DOI: 10.1093/oncolo/oyad119
关键词
asciminib; chronic myeloid leukemia; EMA; tyrosine kinase inhibitor; BCR-ABL1
类别
Asciminib is an effective treatment option for patients with Philadelphia chromosome-positive chronic myeloid leukemia who have previously been treated with at least 2 TKIs. The clinical study demonstrated that asciminib had a higher MMR rate compared to the control group, indicating its efficacy and safety.
Asciminib is an allosteric high-affinity tyrosine kinase inhibitor (TKI) of the BCR-ABL1 protein kinase. This kinase is translated from the Philadelphia chromosome in chronic myeloid leukemia (CML). Marketing authorization for asciminib was granted on August 25, 2022 by the European Commission. The approved indication was for patients with Philadelphia chromosome-positive CML in the chronic phase which have previously been treated with at least 2 TKIs. Clinical efficacy and safety of asciminib were evaluated in the open-label, randomized, phase III ASCEMBL study. The primary endpoint of this trial was major molecular response (MMR) rate at 24 weeks. A significant difference in MRR rate was shown between the asciminib treated population and the bosutinib control group (25.5% vs. 13.2%, respectively, P =.029). In the asciminib cohort, adverse reactions of at least grade 3 with an incidence >= 5% were thrombocytopenia, neutropenia, increased pancreatic enzymes, hypertension, and anemia. The aim of this article is to summarize the scientific review of the application which led to the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据